Evidence map›Paper›PMID 31068371›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.

Hong-Wei Wu, Michael A Sheard, Jemily Malvar, G Esteban Fernandez, Yves A DeClerck, Laurence Blavier, Hiroyuki Shimada, Charles P Theuer, Richard Sposto, Robert C Seeger

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. The combination therapy of oncolytic virotherapy.Frontiers in pharmacology · 2024
    Review
  14. Article
  15. Targeting the myeloid microenvironment in neuroblastoma.Journal of experimental & clinical cancer research : CR · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hong-Wei WuChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
Michael A SheardChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.ORCID 0000-0002-4960-7650
Jemily MalvarChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
G Esteban FernandezChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
Yves A DeClerckChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
Laurence BlavierChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
Hiroyuki ShimadaChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
Charles P TheuerTRACON Pharmaceuticals, Inc., San Diego, California.
Richard SpostoChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California.
Robert C SeegerChildren's Hospital Los Angeles and the Saban Research Institute, Los Angeles, California. rseeger@chla.usc.edu.
Children's Hospital of Los Angeles · USUniversity of Southern California · USTracon Pharmaceuticals (United States) · US

Funding

Vascular endothelial cell integrins in angiogenesisP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI SEEGER, ROBERT CHARLES · 2000 to 2014
$28.5M
Tumor microenvironment-dependent therapy resistanceP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$20.7M
NCI NIH HHS P01 CA081403NCI NIH HHS P01 CA217959
6 · The paper itself

Abstract

purposeWe determined whether elimination of CD105 EXPERIMENTAL

designThe effect of MSCs and monocytes on antibody-dependent cellular cytotoxicity (ADCC) mediated by dinutuximab with aNK cells against neuroblastoma cells was determined

resultsADCC mediated by dinutuximab with aNK cells against neuroblastoma cells

conclusionsImmunotherapy of neuroblastoma with anti-GD2 antibody dinutuximab and aNK cells is suppressed by CD105

Indexed as

AnimalsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCell Line, TumorEndoglinGangliosidesHumansImmunotherapyKiller Cells, NaturalMiceMice, Inbred NODMice, SCIDNeuroblastomaXenograft Model Antitumor AssaysAntibodies, MonoclonalAntineoplastic AgentscarotuximabdinutuximabEndoglinENG protein, humanganglioside, GD2Gangliosides

Identifiers

PMID31068371
PMCPMC6738573
OpenAlexW2944609433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.